|
|
 |
Home |
|
|
|
About |
|
|
|
Products |
|
|
|
Research |
|
|
|
Markets |
|
|
|
Contact |
|
|
|
News |
|
|
Company News
August, 2011 - Dr. Nik Rao at the H. Lee Moffitt Cancer Center (Tampa, FL) begins patient enrollment in a Phase I/II clinical trial to determine the safety and efficacy in radiation alopecia prevention of topically applied ProDermaCel vasoconstrictor in post-surgical head and neck patients receiving cranial radiotherapy.
March, 2011 - ProCertus BioPharm, Inc. closes $1.77 million Series A Financing led by Novartis Venture Fund, Venture Investors, LLC and the Wisconsin Alumni Research Foundation.
March, 2011 - United States Patent & Trademark Office indicates that patent covering the inventive technology in the ProCertus DermX, ProDermaCel and OralX development-stage products will issue soon.
February, 2011 - Dr. James Cleary and Dr. George Cannon at the University of Wisconsin Carbone Cancer Center begin patient enrollment in a Phase I/II clinical trial to determine the safety and efficacy in radiodermatitis prevention of topically applied DermX vasoconstrictor in post-surgical breast cancer patients receiving 50-60 Gy radiotherapy course to prevent cancer.
June, 2009 - Dr. James Cleary and Dr. Deepak Khuntia at the University of Wisconsin Carbone Cancer Center begin patient enrollment in a Phase I/II clinical trial to determine the safety and efficacy in radiodermatitis prevention of topically applied vasoconstrictor in patients receiving radiotherapy to treat bone metastases.
June 29, 2009 - Milwaukee Journal Sentinel interviews acting CEO (Paul Weiss) about opened clinical trials and ProCertus product development.
June 30, 2009 - ProCertus BioPharm, Inc. closes $1.05 Million Series A Financing led by Novartis Venture Fund and Venture Investors, LLC.
May, 2008 - Investigators (Dr. James Cleary et al.) at University of Wisconsin Carbone Cancer Center complete Phase I clinical study of DermX/ProDermaCel™ technology. Normal subjects receiving six week topical application of DermX formulation demonstrated: i) no significant topical or systemic toxicities over the six week drug course at any of the scheduled doses, ii) successful compliance with the topical drug application schedule that involved five applications per week x six weeks, and iii) successful induction of the scored skin endpoint that predicted complete radioprotection in animal models of radiodermatitis.
May 14, 2007 - Wall Street Reporter web interviews CSO (Fahl) about ProCertus product development.
May 10, 2007 - ProCertus BioPharm, Inc. closes $2.3 Million Series A Financing Led by Venture Investors LLC.
Spring '07 - ProCertus is featured Company in Research Digest